Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 31, 2007

 

Panacos Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware   0-24241   11-3238476
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

134 Coolidge Avenue

Watertown, Massachusetts 02472

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (617) 926-1551

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

ITEM 7.01 REGULATION FD DISCLOSURE.

On August 31, 2007, Panacos Pharmaceuticals, Inc. (“Panacos” or the “Company”) announced that it will present at the 20th Annual Bear Stearns Healthcare Conference, to be held from September 10-11 at The Grand Hyatt in New York, NY. Dr. Alan W. Dunton, Panacos’ President and CEO, will also present an overview of the Company and a development update at that meeting. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

The information in this Form 8-K related to the 20th Annual Bear Stearns Healthcare Conference and Dr. Dunton’s presentation shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

 

Exhibit No.

   

Exhibit

99.1

    Press release of Panacos Pharmaceuticals, Inc. dated August 31, 2007 announcing that it will present at the 20th Annual Bear Stearns Healthcare Conference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PANACOS PHARMACEUTICALS, INC.

Dated: August 31, 2007

   By:  

/s/ Peyton J. Marshall

    Peyton J. Marshall, Ph.D.
    Executive Vice President and Chief Financial Officer

EXHIBIT INDEX

 

Exhibit No.

   

Exhibit

99.1

   

Press release of Panacos Pharmaceuticals, Inc. dated August 31, 2007 announcing that it will present at the 20th Annual

Bear Stearns Healthcare Conference.